BioMarin Pharmaceutical: VOXZOGO Triggers Strong Growth in Q4 - Forecast for 2025 Shatters Expectations!

BioMarin Pharmaceutical Inc. (BMRN) focuses on the development and commercialization of innovative therapies for rare genetic diseases. The company employs state-of-the-art biotechnological approaches, including enzyme replacement therapies, gene therapies, and RNA-based drugs, to assist patients with severe, often untreated conditions. The pipeline is well-established, with experts particularly focused on four candidates. The first candidate is BMN 333. In January 2025, the first clinical study began with this long-acting C-type natriuretic...